Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief

Alessio Moriconi, Thiago M. Cunha, Guilherme R. Souza, Alexandre H. Lopes, Fernando Q. Cunha, Victor L. Carneiro, Larissa G. Pinto, Laura Brandolini, Andrea Aramini, Cinzia Bizzarri, Gianluca Bianchini, Andrea R. Beccari, Marco Fanton, Agostino Bruno, Gabriele Costantino, Riccardo Bertini, Emanuela Galliera, Massimo Locati, Sérgio H. Ferreira, Mauro M. TeixeiraMarcello Allegretti

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Chronic pain resulting from inflammatory and neuropathic disorders causes considerable economic and social burden. Pharmacological therapies currently available for certain types of pain are only partially effective and may cause severe adverse side effects. The C5a anaphylatoxin acting on its cognate G protein-coupled receptor (GPCR), C5aR, is a potent pronociceptive mediator in several models of inflammatory and neuropathic pain. Although there has long been interest in the identification of C5aR inhibitors, their development has been complicated, as for many peptidomimetic drugs, mostly by poor drug-like properties. Herein, we report the de novo design of a potent and selective C5aR noncompetitive allosteric inhibitor, DF2593A, guided by the hypothesis that an allosteric site, the "minor pocket," previously characterized in CXC chemokine receptors-1 and -2, is functionally conserved in the GPCR class. In vitro, DF2593A potently inhibited C5a-induced migration of human and rodent neutrophils. In vivo, oral administration of DF2593A effectively reduced mechanical hyperalgesia in several models of acute and chronic inflammatory and neuropathic pain, without any apparent side effects. Mechanical hyperalgesia after spared nerve injury was also reduced in C5aR-/- mice compared with WT mice. Furthermore, treatment of C5aR-/- mice with DF2593A did not produce any further antinociceptive effect compared with C5aR-/- mice treated with vehicle. The successful medicinal chemistry strategy confirms that a conserved minor pocket is amenable for the rational design of selective inhibitors and the pharmacological results support that the allosteric blockade of the C5aR represents a highly promising therapeutic approach to control chronic inflammatory and neuropathic pain.

Original languageEnglish
Pages (from-to)16937-16942
Number of pages6
JournalProceedings of the National Academy of Sciences of the United States of America
Volume111
Issue number47
DOIs
Publication statusPublished - Nov 25 2014

Fingerprint

Neuralgia
Chronic Pain
Hyperalgesia
G-Protein-Coupled Receptors
Interleukin-8A Receptors
Interleukin-8B Receptors
Anaphylatoxins
Pharmacology
Allosteric Site
Peptidomimetics
Pharmaceutical Chemistry
Pharmaceutical Preparations
Oral Administration
Rodentia
Neutrophils
Therapeutics
Economics
Pain
Wounds and Injuries

Keywords

  • Allosteric antagonism
  • C5a
  • GPCR
  • Inflammatory pain
  • Neuropathic pain

ASJC Scopus subject areas

  • General

Cite this

Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief. / Moriconi, Alessio; Cunha, Thiago M.; Souza, Guilherme R.; Lopes, Alexandre H.; Cunha, Fernando Q.; Carneiro, Victor L.; Pinto, Larissa G.; Brandolini, Laura; Aramini, Andrea; Bizzarri, Cinzia; Bianchini, Gianluca; Beccari, Andrea R.; Fanton, Marco; Bruno, Agostino; Costantino, Gabriele; Bertini, Riccardo; Galliera, Emanuela; Locati, Massimo; Ferreira, Sérgio H.; Teixeira, Mauro M.; Allegretti, Marcello.

In: Proceedings of the National Academy of Sciences of the United States of America, Vol. 111, No. 47, 25.11.2014, p. 16937-16942.

Research output: Contribution to journalArticle

Moriconi, A, Cunha, TM, Souza, GR, Lopes, AH, Cunha, FQ, Carneiro, VL, Pinto, LG, Brandolini, L, Aramini, A, Bizzarri, C, Bianchini, G, Beccari, AR, Fanton, M, Bruno, A, Costantino, G, Bertini, R, Galliera, E, Locati, M, Ferreira, SH, Teixeira, MM & Allegretti, M 2014, 'Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief', Proceedings of the National Academy of Sciences of the United States of America, vol. 111, no. 47, pp. 16937-16942. https://doi.org/10.1073/pnas.1417365111
Moriconi, Alessio ; Cunha, Thiago M. ; Souza, Guilherme R. ; Lopes, Alexandre H. ; Cunha, Fernando Q. ; Carneiro, Victor L. ; Pinto, Larissa G. ; Brandolini, Laura ; Aramini, Andrea ; Bizzarri, Cinzia ; Bianchini, Gianluca ; Beccari, Andrea R. ; Fanton, Marco ; Bruno, Agostino ; Costantino, Gabriele ; Bertini, Riccardo ; Galliera, Emanuela ; Locati, Massimo ; Ferreira, Sérgio H. ; Teixeira, Mauro M. ; Allegretti, Marcello. / Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief. In: Proceedings of the National Academy of Sciences of the United States of America. 2014 ; Vol. 111, No. 47. pp. 16937-16942.
@article{6ea1dd1801474dccbc478d84536e146a,
title = "Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief",
abstract = "Chronic pain resulting from inflammatory and neuropathic disorders causes considerable economic and social burden. Pharmacological therapies currently available for certain types of pain are only partially effective and may cause severe adverse side effects. The C5a anaphylatoxin acting on its cognate G protein-coupled receptor (GPCR), C5aR, is a potent pronociceptive mediator in several models of inflammatory and neuropathic pain. Although there has long been interest in the identification of C5aR inhibitors, their development has been complicated, as for many peptidomimetic drugs, mostly by poor drug-like properties. Herein, we report the de novo design of a potent and selective C5aR noncompetitive allosteric inhibitor, DF2593A, guided by the hypothesis that an allosteric site, the {"}minor pocket,{"} previously characterized in CXC chemokine receptors-1 and -2, is functionally conserved in the GPCR class. In vitro, DF2593A potently inhibited C5a-induced migration of human and rodent neutrophils. In vivo, oral administration of DF2593A effectively reduced mechanical hyperalgesia in several models of acute and chronic inflammatory and neuropathic pain, without any apparent side effects. Mechanical hyperalgesia after spared nerve injury was also reduced in C5aR-/- mice compared with WT mice. Furthermore, treatment of C5aR-/- mice with DF2593A did not produce any further antinociceptive effect compared with C5aR-/- mice treated with vehicle. The successful medicinal chemistry strategy confirms that a conserved minor pocket is amenable for the rational design of selective inhibitors and the pharmacological results support that the allosteric blockade of the C5aR represents a highly promising therapeutic approach to control chronic inflammatory and neuropathic pain.",
keywords = "Allosteric antagonism, C5a, GPCR, Inflammatory pain, Neuropathic pain",
author = "Alessio Moriconi and Cunha, {Thiago M.} and Souza, {Guilherme R.} and Lopes, {Alexandre H.} and Cunha, {Fernando Q.} and Carneiro, {Victor L.} and Pinto, {Larissa G.} and Laura Brandolini and Andrea Aramini and Cinzia Bizzarri and Gianluca Bianchini and Beccari, {Andrea R.} and Marco Fanton and Agostino Bruno and Gabriele Costantino and Riccardo Bertini and Emanuela Galliera and Massimo Locati and Ferreira, {S{\'e}rgio H.} and Teixeira, {Mauro M.} and Marcello Allegretti",
year = "2014",
month = "11",
day = "25",
doi = "10.1073/pnas.1417365111",
language = "English",
volume = "111",
pages = "16937--16942",
journal = "Proceedings of the National Academy of Sciences of the United States of America",
issn = "0027-8424",
number = "47",

}

TY - JOUR

T1 - Targeting the minor pocket of C5aR for the rational design of an oral allosteric inhibitor for inflammatory and neuropathic pain relief

AU - Moriconi, Alessio

AU - Cunha, Thiago M.

AU - Souza, Guilherme R.

AU - Lopes, Alexandre H.

AU - Cunha, Fernando Q.

AU - Carneiro, Victor L.

AU - Pinto, Larissa G.

AU - Brandolini, Laura

AU - Aramini, Andrea

AU - Bizzarri, Cinzia

AU - Bianchini, Gianluca

AU - Beccari, Andrea R.

AU - Fanton, Marco

AU - Bruno, Agostino

AU - Costantino, Gabriele

AU - Bertini, Riccardo

AU - Galliera, Emanuela

AU - Locati, Massimo

AU - Ferreira, Sérgio H.

AU - Teixeira, Mauro M.

AU - Allegretti, Marcello

PY - 2014/11/25

Y1 - 2014/11/25

N2 - Chronic pain resulting from inflammatory and neuropathic disorders causes considerable economic and social burden. Pharmacological therapies currently available for certain types of pain are only partially effective and may cause severe adverse side effects. The C5a anaphylatoxin acting on its cognate G protein-coupled receptor (GPCR), C5aR, is a potent pronociceptive mediator in several models of inflammatory and neuropathic pain. Although there has long been interest in the identification of C5aR inhibitors, their development has been complicated, as for many peptidomimetic drugs, mostly by poor drug-like properties. Herein, we report the de novo design of a potent and selective C5aR noncompetitive allosteric inhibitor, DF2593A, guided by the hypothesis that an allosteric site, the "minor pocket," previously characterized in CXC chemokine receptors-1 and -2, is functionally conserved in the GPCR class. In vitro, DF2593A potently inhibited C5a-induced migration of human and rodent neutrophils. In vivo, oral administration of DF2593A effectively reduced mechanical hyperalgesia in several models of acute and chronic inflammatory and neuropathic pain, without any apparent side effects. Mechanical hyperalgesia after spared nerve injury was also reduced in C5aR-/- mice compared with WT mice. Furthermore, treatment of C5aR-/- mice with DF2593A did not produce any further antinociceptive effect compared with C5aR-/- mice treated with vehicle. The successful medicinal chemistry strategy confirms that a conserved minor pocket is amenable for the rational design of selective inhibitors and the pharmacological results support that the allosteric blockade of the C5aR represents a highly promising therapeutic approach to control chronic inflammatory and neuropathic pain.

AB - Chronic pain resulting from inflammatory and neuropathic disorders causes considerable economic and social burden. Pharmacological therapies currently available for certain types of pain are only partially effective and may cause severe adverse side effects. The C5a anaphylatoxin acting on its cognate G protein-coupled receptor (GPCR), C5aR, is a potent pronociceptive mediator in several models of inflammatory and neuropathic pain. Although there has long been interest in the identification of C5aR inhibitors, their development has been complicated, as for many peptidomimetic drugs, mostly by poor drug-like properties. Herein, we report the de novo design of a potent and selective C5aR noncompetitive allosteric inhibitor, DF2593A, guided by the hypothesis that an allosteric site, the "minor pocket," previously characterized in CXC chemokine receptors-1 and -2, is functionally conserved in the GPCR class. In vitro, DF2593A potently inhibited C5a-induced migration of human and rodent neutrophils. In vivo, oral administration of DF2593A effectively reduced mechanical hyperalgesia in several models of acute and chronic inflammatory and neuropathic pain, without any apparent side effects. Mechanical hyperalgesia after spared nerve injury was also reduced in C5aR-/- mice compared with WT mice. Furthermore, treatment of C5aR-/- mice with DF2593A did not produce any further antinociceptive effect compared with C5aR-/- mice treated with vehicle. The successful medicinal chemistry strategy confirms that a conserved minor pocket is amenable for the rational design of selective inhibitors and the pharmacological results support that the allosteric blockade of the C5aR represents a highly promising therapeutic approach to control chronic inflammatory and neuropathic pain.

KW - Allosteric antagonism

KW - C5a

KW - GPCR

KW - Inflammatory pain

KW - Neuropathic pain

UR - http://www.scopus.com/inward/record.url?scp=84912550371&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912550371&partnerID=8YFLogxK

U2 - 10.1073/pnas.1417365111

DO - 10.1073/pnas.1417365111

M3 - Article

C2 - 25385614

AN - SCOPUS:84912550371

VL - 111

SP - 16937

EP - 16942

JO - Proceedings of the National Academy of Sciences of the United States of America

JF - Proceedings of the National Academy of Sciences of the United States of America

SN - 0027-8424

IS - 47

ER -